ESR1 and breast cancer: Tamoxifen is most commonly used in ER + BC (Legha, 1988; Yang et al., 2013), Toremifene has a comparable efficacy of Tamoxifen (Zhou et al., 2011), and Fulvestrant is the latest generation of ER inhibitor for the treatment of ER + BC (Chen P. et al., 2022).